Acute exacerbations of chronic bronchitis: What role for the new fluoroquinolones?

Drugs and Aging

Volumn 18, Issue 1, 2001, Pages 1-11

  Obaji, Adel ^a   Sethi, Sanjay ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

AGED; ANTIMICROBIAL ACTIVITY; CARDIOTOXICITY; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; DISEASE EXACERBATION; DROWSINESS; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; GRAM NEGATIVE BACTERIUM; HEADACHE; HUMAN; INSOMNIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; QT INTERVAL; REVIEW; TORSADE DES POINTES; TREATMENT OUTCOME; VERTIGO;

ANTI-INFECTIVE AGENTS; BRONCHITIS; CHRONIC DISEASE; CLINICAL TRIALS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; SPUTUM; STREPTOCOCCUS PNEUMONIAE;

EID: 0035119205     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118010-00001     Document Type: Review

References (50)

1. Morbidity and mortality chartbook on cardiovascular, lung and blood diseases
2. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians
3. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada. 1997)
4. Prevalence of antimicrobial resistance amount respiratory tract isolates of Streplococcus pneumoniae in North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program
5. Bacterial infection in chronic obstructive pulmonary disease
6. Etiology and management of infections in chronic obstructive pulmonary disease
7. The next generation: Fluoroquinolones in the management of acute lower respiratory infection in adults
8. What is the place ol fluoroquinolones in the treatment of community-acquired respiratory tract infections?
9. Fluoroquinolone resistance: Overuse of fluoroquinotones in human and veterinary medicine can breed resistance
10. Expanding uses of flouroquinolones: Opportunities and challenges
11. Therapy for pneumococcal infection at the millennium: Doubts and certainties
12. Five-day moxifloxacin therapy compared with 7-day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis
13. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized, double-blind study
14. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis
15. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis
16. Randomized, doubleblind study of grepafloxacin versus amoxicillin in patients with acute bacterial exacerbations of chronic bronchitis
17. Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis
18. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis
19. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: The relationship with in vitro activity
20. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily
21. Randomized, doubleblind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis
22. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
23. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: A multicenter, double-blind, randomized, comparative study
24. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A doubleblind, randomised, parallel, multicentre study
25. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg BID vs clarithromycin 500 mg BID
26. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones
27. Decreased susceptibility of Streptococcus pneumoniae to flouroquinolones in Canada
28. Fluoroquinolone resistance in Streptococcus pneumoniae
29. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract
30. Moxifloxacin
31. Gatifloxacin
32. Sparfloxacin: A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections
33. Levofloxacin and sparfloxacin: New quinolone antibiotics
34. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone
35. Quinolone pharmacokinetics in the elderly
36. Clinical pharmacology of gatifioxacin, a new fluoroquinolone
37. Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp
38. Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity
39. Use of antibiotics inpreventing recurrent acute otitis media and in treating otitis media with effusion
40. Fluoroquinolone toxicity profiles: A review focusing on newer agents
41. QT-interval prolongation by non-cardiac drugs lessons to be learned from recent experience
42. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect
43. Fluoroquinolone phototoxicity: A comparison of moxifloxacin and lomefloxacin in normal volunteers
44. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
45. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae
46. DNA topoisomerase targets of the flouroquinolones: A strategy for avoiding bacterial resistance
47. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation
48. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians
49. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis